What's New at The Body
HIV/AIDS News You Can Use
October 11, 2001
Tenofovir Facts and AccessOne of the most eagerly awaited drugs is tenofovir disoproxil fumarate (Viread). Tim Horn looks at the latest studies in CRIA Update.
In many countries, physicians may now provide tenofovir at no cost for people with HIV/AIDS. This once-a-day medication is meant for people whose previous anti-HIV medications have failed.
To find out more about tenofovir, browse through The Body's rich collection of articles.
Resistance Testing: Frequently Asked QuestionsJust when everyone starts getting used to viral load tests, with all their confusing "logs" and "copies" and "undetectable levels," another family of lab tests with its own bewildering lingo arrives on the scene. Tim Horn explains drug-resistance tests and why they are important in CRIA Update.
Several recent studies show the complexities involved in interpreting the results of resistance tests and make it clear that some fine-tuning is still required. Ben Cheng looks at the data for resistance testing in CRIA Update.
HIV University for WomenL.A. women have a new weapon to fight HIV -- it's called knowledge. Cathy Olufs writes about Women Alive's second annual HIV University learning program for women.
Quality of Life SurveyCRIA Update surveyed its readers on their quality of life. Read the interesting results.
Greed and HIVSome doctors and pharmaceutical companies are profiteering from one of the most lucrative illnesses ever to hit humankind. For the details on exactly how people are getting rich off HIV, click here.
New World AIDS CampaignThis year's World AIDS Campaign will chip away at masculine behaviors and attitudes that contribute to the spread of HIV, according to Dr. Peter Piot, Executive Director of the Joint United Nations Programme on HIV/AIDS (UNAIDS).
AIDS Vaccine Enters Clinical TrialThe first AIDS vaccine made at NIAID's vaccine research center enters clinical trials just one year after NIAID's laboratories open. Click here to read more.
Visual AIDS Newsletter Now OnlineVisual AIDS' Fall newsletter, Art+, is now live! Read the latest news from this great group for HIV-positive artists.
Harm Reduction, Drug Use and HIVMuch of the work on harm reduction has only been in relation to drug use. This fact sheet from New Mexico AIDS InfoNet focuses on harm reduction methods for HIV as well.
Facts About Acute HIV InfectionIt's not easy to identify people with acute HIV infection. Some people have no symptoms and if symptoms do occur, diseases like the flu might be their cause. Read this new fact sheet about acute HIV infection from the New Mexico AIDS InfoNet.
Structured Treatment Interruptions Demystified"Confused about structured treatment interruptions (STIs)? So am I, and I do this for a living! That's why I pulled Jamie aside to explain that SITs/STIs are not a 'Do It Yourself' course offered at Homo Depot." The facts about STIs, from Positively Aware.
New Director for AIDS ActionAIDS Action announces that Harriet C. (Hattie) Babbitt is taking the helm as the organization's next executive director, effective immediately.
The Drug Development PipelineWorried about future HIV drug development? Treatment Action Group has put together a handy chart of all the HIV drugs that are in the development pipeline (including some that were being developed but have been cancelled).
When to Start Treatment RecommendationsDavid Barr from Treatment Action Group revisits the changes to the federal when-to-start recommendations announced earlier this year. He urges us to consider both the roots and the ramifications of this extraordinary development.
Post-Exposure ProphylaxisDid you know that the overall transmission rate of HIV infection following occupational exposure is estimated to be approximately 0.3%? Read Seattle Treatment Project's update on how transmission can be avoided with post-exposure prophylaxis.
To read more on post-exposure prophylaxis, browse through The Body's collection of articles.
Boehringer-Ingelheim Provides Viramune Free to Stop Mother-to-Child TransmissionBoehringer-Ingelheim works to make nevirapine available to prevent mother-to-child transmission of HIV, read the details from Seattle Treatment Project.